Skip to main content
JG

John Green

3episodes
3podcasts

Featured On 3 Podcasts

All Appearances

3 episodes

AI Summary

→ WHAT IT COVERS Author John Green, who has lived with OCD and major depression for over 25 years, shares his practical mental health toolkit with Dan Harris. Topics include managing intrusive thought spirals, shame reduction through naming, finding purpose through collaboration, maintaining hope amid injustice, and the tradeoffs of public vulnerability. → KEY INSIGHTS - **Toolkit over time:** Building a mental health toolkit across 25 years doesn't eliminate difficult periods but reduces both their intensity and duration. Green notes that in his twenties, depression felt permanent and inescapable. With accumulated strategies, the same challenges now feel more contained, making it possible to sustain a productive, connected life alongside a serious mental illness diagnosis. - **Thought spiral management:** OCD-driven intrusive thoughts function like a blizzard — starting with three or four snowflakes before becoming blinding. The evidence-based reframe is recognizing thoughts as just thoughts, not predictions or commands. Practically, this means watching thoughts pass like cars on a street rather than climbing in to investigate — a distinction Green credits with measurable day-to-day relief. - **Shame reduction through naming:** Borrowing from Fred Rogers' principle that anything mentionable is manageable, Green deliberately gives language and structure to formless internal experiences. Writing the novel Turtles All the Way Down required naming OCD thought spirals precisely enough for readers to experience them, not just observe them — a process that made his own shame more workable and less paralyzing. - **Outward focus and scope management:** Turning attention toward external problems reduces psychological paralysis, but only when scoped narrowly. Green avoids scanning every crisis simultaneously, which triggers decision paralysis. Instead, he takes a long-term view on specific issues like tuberculosis and child mortality — noting child deaths under five dropped from 12 million to 5 million annually over roughly 25 years through deliberate collective effort. - **Identity diversification:** Placing professional identity — book sales, video metrics, audience numbers — at the center of self-worth creates fragility because those metrics are easily measured and constantly visible. Green distributes identity across roles as parent, spouse, sibling, and collaborator. He also reframes productivity to include generating joy, memory, and connection, not only measurable creative output. → NOTABLE MOMENT Green describes a passage from his tuberculosis book where he raises the possibility that his OCD — specifically his fear of microbes — may itself be caused by his gut microbiome, meaning the very organisms he obsesses over could be generating the obsession itself. 💼 SPONSORS [{"name": "Paleo Valley", "url": "https://paleovalley.com/happier"}, {"name": "Square", "url": "https://square.com/go/happier"}, {"name": "Gainbridge", "url": "https://gainbridge.com"}, {"name": "LinkedIn Ads", "url": "https://linkedin.com/happier"}, {"name": "Bombas", "url": "https://bombas.com/happier"}, {"name": "Wayfair", "url": "https://wayfair.com"}] 🏷️ OCD Management, Mental Health Toolkit, Intrusive Thoughts, Hope and Meaning, Shame Reduction

Drug Story

John Green and Tuberculosis

Drug Story
45 minAuthor and YouTuber

AI Summary

→ WHAT IT COVERS Author John Green and journalist Dan Weissman examine how Johnson & Johnson used secondary drug patents to restrict access to bedaquiline, a tuberculosis drug, affecting an estimated 1.4 million patients annually. India's Section 3D patent law, two TB survivors' legal victory, and Green's nerdfighter community combined to pressure J&J into expanding generic access. → KEY INSIGHTS - **Patent Evergreening Mechanics:** Drug companies routinely file dozens of secondary patents on existing drugs to extend monopoly protection far beyond the standard 20-year term. A study of the 12 best-selling US drugs found an average of 131 patents each, translating to an average of 38 years of effective patent protection rather than 20. - **India's Section 3D as a Legal Tool:** India's patent law requires companies seeking secondary patents on existing drug formulations to prove increased therapeutic efficacy — not just a reformulation. This provision successfully blocked J&J's secondary bedaquiline patent in March 2023, immediately enabling Indian generic manufacturers to produce affordable versions of the drug. - **Strategic Patent Filing Timing:** Pharmaceutical companies deliberately delay filing secondary patents to maximize back-end protection. One patent attorney's documented advice instructs companies to wait two to three years during drug discovery before filing add-on patents. J&J waited four years before filing bedaquiline's salt formulation patent, extending their monopoly accordingly. - **Coordinated Advocacy Sequencing:** Effective pharmaceutical advocacy requires layering legal challenges, survivor testimony, and mass public pressure in sequence. Tahir Amin's IMAK spent nearly 20 years building India's legal framework; TB survivors Fumesa Tesile and Nandita Venkateshian filed the patent challenge; only then did John Green's audience amplify pressure — producing J&J's policy concession within one week. - **US Patent Policy Has Global Consequences:** IMAK shifted 80% of its work to the United States because US patent office practices and World Trade Organization policies shaped by US pharmaceutical companies set global standards. Reforming how the US Patent Office evaluates and grants secondary drug patents would directly affect drug access in low- and middle-income countries worldwide. → NOTABLE MOMENT When John Green visited a TB hospital in Sierra Leone, a seemingly energetic nine-year-old boy gave him a full facility tour. Doctors later revealed the child was actually a severely malnourished 16-year-old whose multidrug-resistant TB treatment was failing — and who needed bedaquiline, then completely unavailable in the country. 💼 SPONSORS None detected 🏷️ Tuberculosis, Drug Patent Reform, Pharmaceutical Evergreening, Global Health Access, Bedaquiline

AI Summary

→ WHAT IT COVERS Author John Green discusses his battle with despair versus hope, why he stopped writing fiction for eight years, and navigating fame's impact on creativity. → KEY INSIGHTS - **Hope Practice:** Green carries a note showing child mortality dropped from 12 million to 5 million since his high school graduation, demonstrating progress requires holding competing realities together. - **Internet Fame Reality:** Online success creates illusion that everyone knows and loves you, but actually no one truly knows you - external validation cannot fill internal emptiness. - **Anxiety Management Strategy:** Short-term anxiety relief like phone scrolling at parties increases long-term anxiety; engaging with people despite initial discomfort provides lasting benefits over avoidance behaviors. - **Fiction Writing Block:** Green stopped novels for eight years because readers assumed autobiographical connections between his OCD and characters, making creative distance impossible in social media age. → NOTABLE MOMENT Green reveals his college creative writing professor publicly announced he had never had sex based on reading his fictional love scene to the entire class. 💼 SPONSORS None detected 🏷️ Mental Health, Creative Writing, Internet Culture, Young Adult Literature

Never miss John Green's insights

Subscribe to get AI-powered summaries of John Green's podcast appearances delivered to your inbox weekly.

Start Free Today

No credit card required • Free tier available